Q32 Bio Inc. (QTTB)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 59/100 (HIGH), 21.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 41.63% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
- Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
- Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
- Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
- Q32 Bio to Participate in Upcoming September Investor Conferences
- Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
- Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
- Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases. — Dermatol Ther (Heidelb) 2026 Oct 1 PMID 42823602
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
- Alopecia Areata: Current and Emerging Therapies. — Drugs 2026 Oct PMID 42616344
- Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. — Lancet 2026 Aug 15 PMID 42594914
- Tape-strip transcriptomics identify immune signatures in cutaneous T-cell lymphoma distinct from benign inflammatory skin diseases. — J Allergy Clin Immunol 2026 Aug 7 PMID 42567485
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Q32 Bio Inc..
Full QTTB Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.